Genta Genasense Fails To Demonstrate “Any Clinical Benefit” Improvements, FDA Tells Cmte.

Latest supplement to support a venous thromboembolism indication for Pfizer’s Fragmin will also be discussed by Oncologic Drugs Advisory Committee Sept. 6.

More from Archive

More from Pink Sheet